Introduction
Major depression (MD) is an important cause of disability as well as financial and emotional burden worldwide. While traditionally the monoaminergic system has been implicated in the pathophysiology and treatment of MD, evidence from clinical, preclinical and postmortem studies are rapidly implicating glutamatergic dysregulation in MD. 1 Accordingly, metabotropic glutamate receptors (mGluRs), which slowly mediate glutamaJ Psychiatry Neurosci 2014;39 (6) treatment strategies, are the heterogeneity of the disorder and its association with other psychiatric and mood disorders, such as bipolar disorder (BD) and schizophrenia.
Major depression with psychotic features (psychotic depression) is classified as a subtype of major depression in DSM-IV. As recently discussed by Rothschild, 2 psychotic depression is associated with BD. Studies have shown that patients with psychotic depression had an increased risk for BD compared with patients with nonpsychotic depression. In contrast, evidence suggests psychotic depression is distinct from schizophrenia. 2 It is necessary to characterize the pathophysiology of depression, including its psychotic and nonpsychotic types, and determine the differences and similarities between BD and schizophrenia, as this has crucial implications for advising the use of certain pharmacotherapeutics.
Several lines of evidence suggest the involvement of the anterior cingulate cortex (ACC) in the pathophysiology of depression. It has critical control over mood, emotion and cognition, as proven by bilateral cingulotomy psychosurgery, which can relieve depression and some psychiatric symptoms. 3 Concurrently, reduced glutamate levels have been reported in the ACC of patients with depression, [4] [5] [6] and this is reflected at the protein level for various markers expressed at the glutamatergic synapse. [7] [8] [9] The involvement of glutamatergic dysfunction in depression may be specific to this brain region, as 1 group found alterations of various postsynaptic glutamatergic proteins (NR1 subunit of the Nmethyl-d-aspartate receptor [NMDAR] , postsynaptic density protein 95 [PSD95] and postsynaptic density protein 93 [PSD93]) in the ACC, but not in the dorsolateral prefrontal cortex (DLPFC), in individuals with depression. 7 Metabotropic glutamate receptors, particularly mGluR2/3 and mGluR5, have been identified as novel thera peutic targets for mood and psychiatric disorders because of their ability to modulate glutamatergic neurotransmission. [10] [11] [12] Whereas mGluR2/3 are predominately presynaptic receptors that inhibit glutamate and γ-aminobutyric acid (GABA) release into the synapse, 13 mGluR5 are primarily expressed postsynaptically, where they modulate the glutamate response, especially in association with the NMDAR. 11 In addition to their therapeutic potential, mGluRs are also implicated in the pathophysiology of these disorders. For example, numerous animal studies demonstrate that selected mGluRs are affected in animal models of depression, 14, 15 and knockout animals display psychotic pheno typic behaviours. 11, 13 From these studies, it is becoming increasingly clear that there may be opposing actions of the glutamatergic system in these disorders, particularly as mGluR2/3 and mGluR5 blockade appear to be beneficial for the treatment of depression, while potentiation of these receptors has preclinical efficacy for the treatment of psychosis. 1, 11, 13 Hence, mGluR2/3 and mGluR5 may be differentially involved in the pathophysiology of mood and psychotic disorders.
We sought to determine whether mGluR2/3 and mGluR5 were altered in the ACC of individuals with MD (in the presence and absence of psychosis) and the associated pathologies BD and schizophrenia. We studied 2 independent postmortem cohorts from the Stanley Medical Research Institute: the Stanley Depression Collection, consisting of samples from individuals who had MD without psychosis (MDNP), MD with psychosis (MDP) and controls, and the Stanley Neuropathology Consortium, consisting of samples from individuals who had diagnoses of MDNP, BD and schizophrenia and controls. We measured mGluR2/3 and mGluR5 binding in the ACC (Brodmann area [BA] 24) of these samples by in situ receptor autoradiography. As the ACC is implicated in the emotional and cognitive deficits associated with these disorders, the findings from this study have translational implications for novel drugs aimed to treat mood and cognitive deficits in patients with these disorders.
Methods

Human postmortem brain samples
Frozen postmortem brain tissue was acquired through the Stanley Medical Research Institute. From the Depression Collection, we obtained samples from 24 individuals who had MD (MDNP: n = 12; MDP: n = 11) and controls (n = 12) matched according to age, postmortem interval (PMI), refriger ation interval and brain pH (Table 1) . Psychosis could not be confirmed in 1 of the MD samples, who was therefore excluded from psychosis-specific analyses. From the Neuropathology Consortium, we obtained samples from 60 individuals who had MDNP, BD and schizophrenia and controls (n = 15 per group), matched for age, sex, race and PMI (Table 2) . Detailed clinical and demographic information regarding these cohorts have been published previously. 16, 17 The work described in this study was approved by the Human Research Ethics Committee at the University of Wollongong and conducted according to their guidelines (HE13/069).
Receptor autoradiography
Frozen coronal sections at the level of the ACC (BA24; 14 µm) were mounted onto slides and stored at -80°C until the day of the assay. Receptor autoradiography studies were based on protocols described previously (mGluR2/3; 18, 19 mGluR5 20, 21 ). Autoradiography exposures were optimized for mGluR2/3 and mGluR5 to ensure that each cortical layer could be quantified on a linear scale and none of the cortical layers with high expression were overexposed. The signal to noise ratio of mGluR2/3 and mGluR5 binding in all groups assayed were well above the nonspecific control. Two sections for each individual were analyzed for total binding, and adjacent sections were used to determine nonspecific binding. All experiments were performed blind to diagnoses. 
Imaging and quantification
Together with [ 3 H] microscale autoradiographic standards (Amersham Biosciences), sections were exposed to tritium sensitive Kodak Biomax MR film (Kodak) for 10 weeks. Films were developed using the AGFA CP1000 film developer (Agfa-Gavaert N.V.), scanned using a GS800 densitometer (BioRad) and analyzed using Multi-Analyst software (BioRad). Quantification was performed blind to diagnoses. Radioligand binding signals were expressed in counts per minute (cpm)/mm 2 and, with the use of standards and the specific activities of the respective radioligands, were converted to fmol/mg tissue equivalents.
Statistical analysis
As data were normally distributed across both cohorts, we used parametric tests. No data points were identified as outliers (± 2 Fluphenazine equivalents -2 242 (100-6 500) 2 533 (100-6 500) 1 367 (100-3 000) MD = major depression; MDNP = major depression without psychosis; MDP = major depression with psychosis; PMI = postmortem interval. *Unless otherwise indicated. †Values refer to the mean interval between patient death and refrigeration of the body at the medical examiner's office. ‡Number of patients with a prescription for antipsychotics at the time of death. 
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standard deviations). The depression collection and the neuropathology consortium were analyzed separately. We used analy sis of variance (ANOVA) followed by a Tukey post hoc test to compare differences in mGluR2/3 and mGluR5 binding between the diagnoses in the 2 cohorts (i.e., MDNP, MDP v. control and MDNP, BD, schizophrenia and control). Subsequently, we completed Pearson correlations to determine any influence of continuous variables on the data. We then carried out analyses of covariance (ANCOVAs) in which we compared binding values between the diagnostic groups in the 2 cohorts, controlling for variables that significantly correlated with the data. Statistical analyses were performed using SPSS software version 19.0. We considered results to be significant at p < 0.05, and data are presented as means ± standard errors of the mean (SEM).
The Stanley Neuropathology Consortium Integrative Database
The Stanley Neuropathology Consortium Integrative Database (SNCID; http://sncid.stanleyresearch.org) 22 includes 1762 pathological markers measured in 12 different brain regions by the Neuropathology Consortium. In line with the hypotheses of the present study, we sought to determine if there were associations between our measures of mGluR2/3 and mGluR5 and measures of other glutamate-related proteins, specifically within the cingulate cortex. Exploratory correlation analyses of glutamatergic markers (various measures of NMDAR, 2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl propionate receptor [AMPAR] and kainate receptors) and signalling partners (PSD95, brain-derived neurotrophic factor [BDNF] and protein kinase C [PKC]) that have previously been measured in the cingulate cortex (BA not specified) was performed using the SNCID as previously described. 22 We used a nonparametric method (Spearman correlation) to minimize effects caused by differences in units and/or distribution patterns. 23 All 60 individuals were included, and significance was set at p < 0.05. Detailed information regarding the measurement and experimental protocol for each marker is available on the SNCID database (http://sncid.stanleyresearch.org).
Results
Distribution
We found that mGluR2/3 ([ (Fig. 1) . Whereas mGluR5 binding was homogeneously distributed across all cortical layers, mGluR2/3 binding showed pronounced layer differences; the superficial one-third of the cortex had significantly higher binding than the lower layers (p < 0.001) and was analyzed accordingly. 
Effects of demographic and clinical variables
Pearson correlations for continuous variables (pH, age at death, PMI, refrigeration interval, brain weight, age at disease onset, duration of illness and lifetime fluphenazine equivalents) are presented in Table 3 and in the Appendix, Table S1 , available at jpn.ca. Age at death was consistently associated with mGluR2/3 binding in the control group Table 3 ). Overall, there was no effect of lifetime antipsychotic exposure on total or lower mGluR2/3 (total: r = -0.289, p = 0.19; lower: r = -0.047, p = 0.84) or mGluR5 (r = 0.005, p = 0.98) in all individuals who had MD (MDNP and MDP), but we observed a negative association with mGluR2/3, specifically in the upper layer (r = -0.460, p = 0.031). Power for the subgroups was notably low (MDNP: n = 3; MDP: n = 9) and was therefore not reported (Table 3) . 
Pearson correlations for mGluR2/3 and mGluR5 with continuous variables (pH, age at death, PMI, freezer storage time, brain weight, age at disease onset, duration of illness, and lifetime fluphenazine equivalents) are presented in Table  4 and in the Appendix, Table S1 . Various correlations for pH, brain weight, PMI and freezer storage time were observed across the diagnostic groups; these were accounted for by ANCOVA and did not affect the diagnostic findings. Consistent with our results in the Depression Collection, age at death had a significant negative effect on mGluR2/3 (Table 4) .
Correlations with glutamatergic markers and signalling partners in the SNCID
Explorative Spearman correlations with the data from the present study and those from previous studies (available in the SNCID) are presented in the Appendix, Table S2 . Various significant associations were observed, both overall and in individual pathologies, between mGluR2/3 and mGluR5 with measures of NMDAR, AMPAR and kainate receptors as well as signalling partners PSD95, PKC and BDNF.
Discussion
The mGluR2/3 and mGluR5 receptors are targets of new therapeutic approaches for psychiatric conditions, including MD, BD and schizophrenia. Furthermore, animal studies have suggested the involvement of these receptors in the pathophysiologies of these disorders. 1, 11 In light of this, we have examined binding to mGluR2/3 and mGluR5 in postmortem brains, specifically the ACC, of individuals with MD (MDP, MDNP), BD and schizophrenia and compared them to matched controls. In particular, we chose the receptor binding technique and radioligands that target the same binding sites as novel drugs currently under development to determine how drugs targeting these receptor sites may be affected in the patient. We report no significant diagnostic alterations of mGluR2/3 binding or mGluR5 binding in the ACC in individuals with these pathologies.
Unaltered levels of mGluR2/3 and mGluR5 in depression (with or without psychosis)
mGluR2/3 and mGluR5 are prominent prospective targets in the treatment of mood disorders, as both clinical and preclinical studies have shown antidepressant properties of antagonists or negative allosteric modulators targeted at mGluR2/3 and mGluR5. 1, 12 To our knowledge, we are the first to report that neither mGluR2/3 nor mGluR5 binding levels are altered in the ACC of individuals with MD, in the presence (MDP) or absence (MDNP) of psychosis. Our results are in line with a previous study reporting unaltered mGluR2 and mGluR3 gene expression in the postmortem ACC of individuals with MD. 9 We found no other studies that have investigated mGluRs in the ACC in individuals with depression. In other brain regions of depressed patients, an increase in mGluR2/3 24 and reduction of mGluR5 protein in the prefrontal cortex (BA10) have been reported, together with reduced (in vivo) prefrontal cortical mGluR5 binding 25 and increased mGluR5 gene expression in the locus coeruleus. 26 Although it is difficult to draw conclusions from only a small number of studies, the inconsistencies between these findings highlight the inherent regional differences in mGluRs in the pathophysiology of MD as well as the importance of considering psychiatric subclass. These prior studies have an important limitation in that they do not distinguish between MDP and MDNP, particularly since differential proteome profiles have been recently reported, specifically between MDNP and MDP. 17 
mGluR2/3 and mGluR5 binding does not differ in BD and schizophrenia compared with depression
In line with depression with and without psychosis we report that mGluR2/3 and mGluR5 binding density are unaltered in the ACC in individuals with schizophrenia and BD. While mGluR binding, to our knowledge, has not previously been measured in individuals with BD, studies in the prefrontal cortex, thalamus and striatum of individuals with schizophrenia have likewise reported no change in mGluR2/3 19, [27] [28] [29] [30] or mGluR5 11, 21 (binding, protein or mRNA). Our findings highlight that in the ACC there are no distinct differences between the overlapping diagnoses of MDNP, MDP, schizophrenia and BD with regards to binding to mGluR2/3 and mGluR5. This suggests that novel pharmacological modulators of mGluR2/3 and mGluR5 may have unhindered binding sites in all these disorders.
It should, however, be noted that there may be wider dysregulations in mGluR2/3 and mGluR5 function that were not measured within the scope of our study or that there may be alterations in other mGluR subtypes dependent on specific brain regions. 12 For example, Volk and colleagues 31 found reductions in mGluR1a mRNA, but not mGluR5, in the prefrontal cortex (BA9 and BA42) of patients with schizophrenia. Conversely another more recent study found mGluR5 mRNA and protein to be reduced specifically in BA9 and the lateral cerebellum in individuals with schizophrenia. 32 These examples highlight the heterogeneity and intricacies of spectrum disorders such as schizophrenia. 33 
Current and novel pharmacotherapy implications
In the present study we found evidence of a negative association between mGluR2/3 binding and antipsychotic dose, specifically in individuals with BD and MD, but not in those with schizophrenia. Previous postmortem studies have reported no association between antipsychotic dose and mGluR2/3 19, 27, 28 or mGluR5, 21 specifically in patients with schizophrenia. Animal studies have reported no effect of antipsychotics on mGluR2/3 34 or mGluR5 binding. 21 The effects of antidepressants have not been as well studied, and while reliable quantitative lifetime antidepressant drug history was not available in the present study, our previous work found no association of antidepressant history and mGluR5 binding and protein in the DLPFC in individuals with schizophrenia. 21 Deschwanden and colleagues, 25 however, found that antidepressant treatment may reduce mGluR5 binding specifically in the precentral gyrus of antemortem patients with MD. Animal studies have shown that tricyclic antidepressant treatment significantly increases mGluR2/3 35 and mGluR5a 36 protein in the rat hippocampus, although another study found that total mGluR5 protein levels were unaltered. 35 To our knowledge, there are no prior studies on antidepressant effects specifically in the ACC to shed light on these findings; therefore, further investigation is required.
The mGluR-targeted modulators have shown promising antipsychotic and antidepressant therapeutic potential in preclinical and clinical studies. Orthosteric and allosteric modulators of mGluRs target binding sites on either the N-terminus (mGluR2/3) or transmembrane (mGluR5) domain, respectively. 1, 11, 13, 37 These orthosteric and allosteric binding sites were the same targets of the radioligands used in the present study. As we report that these binding sites are not altered in the ACC in psychopathology, mGluR2/3 and mGluR5 may be unimpeded targets for novel antidepressant and antipsychotic intervention. As results from recent clinical trials with mGluR modulators indicated that specific single nucleotide polymorphisms (SNPs) were associated with treatment response, 38 further study into these same binding sites in individuals with these SNPs would be of value. In addition, we consistently found a negative correlation between mGluR2/3 binding and age in the control, schizophrenia and MDP groups, with no association in the MDNP and BD groups. Age-related differences in treatment approaches remain an issue, 39 and our findings suggest there may be differential treatment responses to these novel therapeutics depending on the pathology and age of the patient.
Association of mGluRs with markers in the wider glutamatergic system
In addition to the metabotropic group of glutamate receptors, glutamate signalling is also transduced through the ionotropic glutamate receptors NMDAR, AMPAR and kainate receptors. The NMDAR and AMPAR receptors are of particular interest as they signal closely with mGluR5 11 and mGluR2/3, 12 respectively, and novel mGluR2/3-and 5-based drugs are proposed to exert their therapeutic effects, at least partially, through their influence on NMDAR and AMPAR. 11, 12 In addition, PSD-95 is a key signalling partner of mGluR5 as it physically and functionally links it to NMDAR in the postsynapse, while PKC and BDNF are downstream signalling effectors of mGluR5/ NMDAR signalling. 11 We explored the association of mGluR2/3 and mGluR5 measured in the present study in relation to measures of these glutamatergic markers as available on the SNCID. We chose a total of 29 markers representing glutamatergic markers and signalling partners within the cingulate cortex. As expected, we observed a number of differential associations between mGluR2/3, mGluR5 and these glutamatergic markers and signalling partners (see the Appendix, Table S2 ). Many of these associations were specific to 1 of the 3 psychiatric disorders examined, indicating that there may be differential associations in the pathophysiologies of these disorders. However, although correlation analyses are useful to identify associations between markers, they do not indicate causality and must be treated as exploratory. These associations may provide direction for future studies aiming to distinguish pathological differences between these psychiatric disorders.
Limitations
While our findings suggest possible age-related differences between the psychotic and mood components, further analysis in a larger postmortem cohort is required to support this notion. In addition, further studies are required to determine if mGluR2/3 or mGluR5 function or downstream signalling are altered in these pathologies. It should be noted that despite no pathological alteration of mGluR2/3 and mGluR5 binding sites in the present study, the ACC remains highly involved in these pathologies as alterations of various neurotransmitters and their associated receptors have been reported in this brain region. 3, 7, [40] [41] [42] Although our study provides valuable information on these binding sites in psychiatric pathology, additional studies examining binding specifically to membranous mGluR2/3 and mGluR5 and the affinity of novel mGluR2/3-and mGluR5-targeting drugs for these receptors in psychiatric disorders will provide valuable insight into the effectiveness of these drugs in the patient. 33 One confound of postmortem studies in neuropsychiatric disorders, is the presence of comorbid substance abuse, especially alcohol and drug abuse, or at least substantially higher alcohol 43 and illicit drug 44 intake in patients with psychiatric disorders. While reliable quantitative patient histories were not available in the present study, mGluR1/5 densities in the prefrontal cortex may be affected by alcohol, 45 and mGluR2 gene expression was reported to be reduced in the ACC of patients with alcohol addiction. 46 Furthermore, there is a growing body of evidence suggesting that mGluRs may be involved in drug and alcohol addiction disorders. 47 Therefore, the molecular effects of alcohol and drug use should be considered when interpreting the present and prior/future studies.
Conclusion
To our knowledge, we have assessed for the first time mGluR2/3 and mGluR5 binding capacity in the ACC in individuals with MD with and without psychosis as well as those with BD and schizophrenia. While we provide evidence that age is differentially associated with mGluR2/3 binding in individuals with psychotic and mood disorders, we found no alterations in mGluR2/3 or mGluR5 binding compared with controls or between any studied pathological state. This suggests that mGluR2/3-and mGluR5-based therapeutics used to treat emotional and cognitive deficits may have unhindered binding capacity in these pathological states. Future studies may extend on this work by investigating mGluR protein/ mRNA expression and their association with other mGluRs, specifically in the ACC and other brain limbic structures; this would increase our understanding of the role of mGluRs in the neuropathologies of psychiatric disease and elucidate their treatment potential.
